Skip to Content
Merck
  • Carcinogenicity bioassays of bromoacetaldehyde and bromoethanol--potential metabolites of dibromoethane.

Carcinogenicity bioassays of bromoacetaldehyde and bromoethanol--potential metabolites of dibromoethane.

Teratogenesis, carcinogenesis, and mutagenesis (1985-01-01)
B L Van Duuren, I Seidman, S Melchionne, S A Kline
ABSTRACT

1,2-Dibromoethane (DBE) and two of its potential metabolites, bromoethanol (BE) and bromoacetaldehyde (BA), were tested for carcinogenicity in male and female B6C3F1 mice using 30 animals of each sex per group. The carcinogen DBE was included in this assay as a positive control. The compounds were administered in distilled drinking water using equimolar concentrations, 4 mmol, of the chemicals. The dose chosen was based on subchronic bioassays of three months' duration. The chronic tests were continued for approximately 450 days in the case of DBE and approximately 560 days for both BE and BA. DBE induced squamous carcinomas of the forestomach in 22 females and 26 males and squamous papillomas of the esophagus in 3 females. BE induced squamous papillomas of the forestomach only in 10 females and 9 males. BA did not induce a significant incidence of tumors of the forestomach. Significant tumor incidences at other sites were not observed in any groups including the distilled water control group. Based on these findings, it is unlikely that BE or BA are activated carcinogenic intermediates of DBE.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Bromoethanol, 95%
Supelco
2-Bromoethanol, analytical standard